eISSN: 2379-6367
Submit manuscript...
Mini Review Volume 14 Issue 1
GLP-1 agonists and GLP-1/GIP dual agonist use in heart failure with preserved ejection fraction
Chase Reinbolt, Kimberly Sloan, Christian Lumbag, Lauren Carpenter, Kelli Corona, Jessica Huston
Received: February 12, 2026 | Published: February 26, 2026
Citation: Reinbolt C, Sloan K, Lumbag C, et al. GLP-1 agonists and GLP-1/GIP dual agonist use in heart failure with preserved ejection fraction. Pharm Pharmacol Int J. 2026;14(1):12-13. DOI: 10.15406/ppij.2026.14.00487
Abstract
Pharmacotherapeutic options for heart failure with preserved ejection fraction (HFpEF) have been historically limited. While treatment options for those with reduced ejection fraction are numerous, the landscape for patients with HFpEF remains an area of interest for researchers. Though the introduction of glucagon-like peptide-1agonists (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide agonists (GIPs) is widely recognized for its treatment indications in type 2 diabetes mellitus and weight-loss, the underlying mechanism has led to advancements and further research into their potential benefits for patients with heart failure. Some GLP-1s have data highlighting their cardioprotective benefits, whereas others are still being evaluated in clinical studies. Over the past few years, the search for potential cardioprotective benefits as result of GLP-1/GIP therapy has made its way into the HFpEF subpopulation of heart failure. This review serves to present a summary of the emerging data for GLP-1/GIP agonists as it relates to heart failure with HFpEF.
Keywords: GLP-1 receptor agonists, GLP-1/GIP dual agonist, HFpEF, heart failure with preserved ejection fraction
©2026 Reinbolt, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.